A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
To Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
To evaluate the efficacy of MK-8527 qm compared to FTC/TDF ad for the
prevention of HIV-1 infection as assessed by the incidence rate per year of adjudicated HIV-1 infections
Randomized, active-controlled, parallel-group, multisite, double-blind, double dummy
Cisgender men, TGW, TGM, and GNB
Vihiga, Nyamira, Nandi, Kisii, Migori
Kisumu
33 Months
Merck Sharp & Dohme
